Consistent with the breadth of protection, administration of AV‑001/Vasculotide has proven therapeutic benefit in several different in vivo disease models marked by vascular dysfunction, including diabetic wound healing, asthma, atopic dermatitis, diabetic atherosclerosis, metastatic disease and acute lung injury.